Vizinect®

Generic Name: Iodixanol

Iodine Content: 320 mg/mL

Dosage Forms: 20 mL, 50 mL, and 100 mL vials

1. What is Vizinect® and its Uses?

Vizinect® is an isotonic aqueous solution containing iodixanol, a non-ionic, dimeric contrast agent.

Indications in Adults:

• Cardiac angiography
• Cerebral angiography
• Peripheral arteriography
• Abdominal angiography (e.g., DSA)
• Urography and venography
• CT enhancement
• Upper gastrointestinal tract studies
• Arthrography and hysterosalpingography (HSG)
• Spinal, chest, and cervical imaging

Indications in Children:

• Cardiac angiography
• Urography
• CT enhancement
• Upper gastrointestinal tract studies

2. Before Using Vizinect®

Contraindications:

• Hypersensitivity to iodixanol or any component of the formulation
• Thyrotoxicosis
• Intrathecal administration (not approved)

Warnings & Precautions:

• Allergy or asthma history: Use caution; premedication with corticosteroids or H1/H2 antagonists may be considered.
• Risk of severe hypersensitivity reactions, including anaphylaxis; emergency medications and equipment should be available. Monitor patients closely for at least 30 minutes post-injection.
• Thromboembolic events: Rarely, serious events such as myocardial infarction or stroke may occur. Proper catheter technique and hydration are essential.
• Dehydration: Can lead to kidney injury, particularly in elderly, diabetic, or patients with multiple myeloma or renal impairment. Ensure adequate hydration before and after injection.
• Cardiovascular or cerebrovascular disease: Use caution in patients with acute stroke, intracranial bleeding, altered blood-brain barrier, cerebral edema, or demyelinating disease.
• Renal or hepatic impairment: Clearance of iodixanol may be significantly reduced; close monitoring required.
• Metformin use: Suspend metformin at the time of contrast administration and for 48 hours afterward. Restart only after renal function is re-evaluated.
• Special populations: Patients with hyperthyroidism, sickle cell disease, severe heart disease, pulmonary hypertension, atherosclerosis, seizure disorders, myasthenia gravis, or pheochromocytoma require special precautions.

Drug Interactions:

• Loop diuretics: May increase nephrotoxicity risk
• Metformin: Risk of lactic acidosis due to contrast-induced renal impairment
• Radioactive iodine (I-123, I-131): Contrast may interfere with thyroid uptake for 6–8 weeks
• Beta-blockers: May increase risk of hypersensitivity reactions

Pregnancy & Breastfeeding:

• Safety not established in pregnancy; use only if benefits outweigh risks
• Iodixanol is minimally excreted in breast milk; breastfeeding can usually continue
• Neonatal thyroid function should be monitored after maternal contrast exposure

Pediatrics:

• Safe in children >1 year for arterial and IV studies
• Safety data for <1 year limited; close monitoring required in high-risk infants
• Increased risk in children with kidney impairment, dehydration, asthma, or cyanotic/non-cyanotic heart disease

Elderly:

• No major differences in safety compared to younger adults, but use caution due to possible comorbidities and organ dysfunction

Driving & Operating Machinery:

• Avoid for 1 hour post-injection

3. Administration & Dosage

General Instructions:

• Hydrate well before and after the procedure to minimize kidney risk
• Not for intrathecal use; IV only
• Dose, concentration, and injection rate adjusted for patient age, weight, vessel size, flow rate, and imaging technique
• Warm to room or body temperature before injection
• Avoid extravasation, especially in severe vascular disease
• Injection rate should approximate normal blood flow
• Do not mix with other drugs or nutrition lines
• Dose tailored for optimal imaging of target vessels

Dosage:

• Adults and children: Depends on procedure, age, weight, cardiac output, patient condition, and imaging technique

Overdose:

• Rare; treat symptomatically
• Maintain hydration and electrolytes
• Monitor renal function for at least 3 days
• Hemodialysis may be required to remove iodixanol

4. Side Effects

Common:

• Discomfort, warmth, or pain at injection site

Less common:

• Angina, chest pain, headache, migraine, dizziness, altered smell, paresthesia, rash, itching, taste changes, nausea

Severe hypersensitivity (rare):

• Respiratory or skin reactions, angioedema, hypotension, fever, laryngeal edema, bronchospasm, pulmonary edema
• Autoimmune patients: rare vasculitis or Stevens–Johnson-like syndrome

Procedure-specific common reactions:

• HSG: abdominal pain, vaginal bleeding, headache, nausea, fever
• Arthrography: injection site pain
• GI: diarrhea, abdominal pain, nausea

5. Storage

• Store below 30°C, protected from light and moisture, in the original box
• Single-use only; discard any remaining solution
• Keep out of reach of children
• Do not use expired product

References

1. GE Healthcare Visipaque PDF
2. FDA Label Visipaque
3. UpToDate 2023